Safe and stable generation of induced pluripotent stem cells using doggybone DNA vectors.

Molecular Therapy. Methods & Clinical Development Pub Date : 2021-10-05 eCollection Date: 2021-12-10 DOI:10.1016/j.omtm.2021.09.018
Christopher D Thornton, Stuart Fielding, Kinga Karbowniczek, Alicia Roig-Merino, Alysha E Burrows, Lorna M FitzPatrick, Aseel Sharaireh, John P Tite, Sara E Mole, Richard P Harbottle, Lisa J Caproni, Tristan R McKay
{"title":"Safe and stable generation of induced pluripotent stem cells using doggybone DNA vectors.","authors":"Christopher D Thornton,&nbsp;Stuart Fielding,&nbsp;Kinga Karbowniczek,&nbsp;Alicia Roig-Merino,&nbsp;Alysha E Burrows,&nbsp;Lorna M FitzPatrick,&nbsp;Aseel Sharaireh,&nbsp;John P Tite,&nbsp;Sara E Mole,&nbsp;Richard P Harbottle,&nbsp;Lisa J Caproni,&nbsp;Tristan R McKay","doi":"10.1016/j.omtm.2021.09.018","DOIUrl":null,"url":null,"abstract":"<p><p>The application of induced pluripotent stem cells (iPSCs) in advanced therapies is increasing at pace, but concerns remain over their clinical safety profile. We report the first-ever application of doggybone DNA (dbDNA) vectors to generate human iPSCs. dbDNA vectors are closed-capped linear double-stranded DNA gene expression cassettes that contain no bacterial DNA and are amplified by a chemically defined, current good manufacturing practice (cGMP)-compliant methodology. We achieved comparable iPSC reprogramming efficiencies using transiently expressing dbDNA vectors with the same iPSC reprogramming coding sequences as the state-of-the-art OriP/EBNA1 episomal vectors but, crucially, in the absence of p53 shRNA repression. Moreover, persistent expression of EBNA1 from bacterially derived episomes resulted in stimulation of the interferon response, elevated DNA damage, and increased spontaneous differentiation. These cellular activities were diminished or absent in dbDNA-iPSCs, resulting in lines with a greater stability and safety potential for cell therapy.</p>","PeriodicalId":517056,"journal":{"name":"Molecular Therapy. Methods & Clinical Development","volume":" ","pages":"348-358"},"PeriodicalIF":0.0000,"publicationDate":"2021-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/0d/main.PMC8546411.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy. Methods & Clinical Development","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtm.2021.09.018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/10 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

The application of induced pluripotent stem cells (iPSCs) in advanced therapies is increasing at pace, but concerns remain over their clinical safety profile. We report the first-ever application of doggybone DNA (dbDNA) vectors to generate human iPSCs. dbDNA vectors are closed-capped linear double-stranded DNA gene expression cassettes that contain no bacterial DNA and are amplified by a chemically defined, current good manufacturing practice (cGMP)-compliant methodology. We achieved comparable iPSC reprogramming efficiencies using transiently expressing dbDNA vectors with the same iPSC reprogramming coding sequences as the state-of-the-art OriP/EBNA1 episomal vectors but, crucially, in the absence of p53 shRNA repression. Moreover, persistent expression of EBNA1 from bacterially derived episomes resulted in stimulation of the interferon response, elevated DNA damage, and increased spontaneous differentiation. These cellular activities were diminished or absent in dbDNA-iPSCs, resulting in lines with a greater stability and safety potential for cell therapy.

Abstract Image

Abstract Image

Abstract Image

利用狗骨DNA载体安全稳定地生成诱导多能干细胞。
诱导多能干细胞(iPSCs)在先进治疗中的应用正在不断增加,但对其临床安全性的担忧仍然存在。我们报道了首次应用狗骨DNA (dbDNA)载体生成人类iPSCs。dbDNA载体是封闭的线性双链DNA基因表达盒,不含细菌DNA,并通过化学定义的、符合现行良好生产规范(cGMP)的方法进行扩增。我们使用瞬时表达的dbDNA载体实现了与最先进的OriP/EBNA1 episomal载体相同的iPSC重编程效率,但至关重要的是,在没有p53 shRNA抑制的情况下。此外,细菌源性发作中EBNA1的持续表达导致干扰素反应的刺激、DNA损伤的升高和自发分化的增加。在dbDNA-iPSCs中,这些细胞活性减弱或缺失,从而使细胞系具有更大的稳定性和安全性,可用于细胞治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信